Search results for "amp"

showing 10 items of 10184 documents

BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases

2008

Male breast cancer (MBC) is a rare and poorly known disease. Germ-line mutations of BRCA2 and, to lesser extent, BRCA1 genes are the highest risk factors associated with MBC. Interestingly, BRCA2 germ-line rearrangements have been described in high-risk breast/ovarian cancer families which included at least one MBC case. Germ-line mutations of CHEK2 gene have been also implicated in inherited MBC predisposition. The CHEK2 1100delC mutation has been shown to increase the risk of breast cancer in men lacking BRCA1/BRCA2 mutations. Intriguingly, two other CHEK2 mutations (IVS2+1G>A and I157T) and a CHEK2 large genomic deletion (del9-10) have been associated with an elevated risk for prostate c…

AdultMaleCancer Researchendocrine system diseasesGenes BRCA2Genes BRCA1male breast cancerProtein Serine-Threonine KinasesBiologychek2medicine.disease_causeBreast Neoplasms Malebrca1Breast cancerbrca2medicineHumansBRCA1/BRCA2germ-line mutationsMultiplex ligation-dependent probe amplificationmlpaskin and connective tissue diseasesneoplasmsCHEK2Germ-Line MutationGene RearrangementMutationCancerGene rearrangementmedicine.diseaseCheckpoint Kinase 2Oncologylarge genomic rearrangementsMale breast cancerCancer researchbrca1; brca2; chek2; germ-line mutations; large genomic rearrangements; male breast cancer; mlpaBreast diseaseBreast Cancer Research and Treatment
researchProduct

Comparison of prognostic models in patients with advanced Hodgkin disease

2001

Several prognostic systems have been elaborated for patients with Hodgkin disease (HD) over the last 12 years, but early identification of a reasonably large group of both low and high risk, advanced stage patients remains unsatisfactory.Seven well known models were applied to 516 patients with advanced HD, with 315 patients used for the study sample and 201 patients used for the test sample. Individual performances as well as joint performances were analyzed univariately and multivariately in relation to overall survival, recurrence free survival, and time to treatment failure by means of a proportional hazards model.None of the models identified a group containing10% of patients from the …

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentPopulationSample (statistics)DiseaseHodgkin disease; prognosis; modeling; survival; time to treatment failureInternal medicinemedicineHumansIn patientChildeducationTime to treatment failurePrognostic modelsAgededucation.field_of_studyProportional hazards modelbusiness.industryLinear modelMiddle AgedModels TheoreticalPrognosisHodgkin DiseaseSurvival AnalysisSurgeryOncologyFemalebusinessCancer
researchProduct

Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome

2008

Abstract Introduction: Magnesium plays a role in a large number of cellular metabolic reactions. Cetuximab is able to induce hypomagnesemia by interfering with magnesium (Mg2+) transport in the kidney. We designed this trial to investigate if Mg2+ serum level modifications may be related with clinical response and outcome in advanced colorectal cancer patients during treatment with cetuximab plus irinotecan. Experimental Design: Sixty-eight heavily pretreated metastatic colorectal cancer patients were evaluated for Mg2+ serum levels at the following time points: before; 6 hours; and 1, 7, 14, 21, 50, and 92 days after the start of treatment. Results: Basal Mg2+ median levels were significan…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerCetuximabmagnesiumcolorectal cancerAntibodies Monoclonal HumanizedIrinotecanGastroenterologyHypomagnesemiaBasal (phylogenetics)Internal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansMagnesiumEpidermal growth factor receptorNeoplasm MetastasisAgedAged 80 and overCetuximabbiologybusiness.industryCancerAntibodies MonoclonalMiddle Agedmedicine.diseaseIrinotecanGene Expression Regulation NeoplasticEndocrinologyTreatment OutcomeOncologyMonoclonalbiology.proteinDisease ProgressionCamptothecinFemalebusinessColorectal Neoplasmsmedicine.drug
researchProduct

Randomized Multicenter Phase II Trial of Two Different Schedules of Irinotecan Combined with Capecitabine as First-Line Treatment in Metastatic Color…

2004

BACKGROUND The aim of the current randomized Phase II study was to investigate the efficacy and safety of capecitabine combined with irinotecan as first-line treatment in metastatic colorectal carcinoma (CRC). METHODS A total of 140 patients received capecitabine at a dose of 1250 mg/m2 twice daily on Days 2–15 and irinotecan at a dose of either 300 mg/m2 on Day 1 (Arm A) or 150 mg/m2 on Days 1 and 8 (Arm B) every 3 weeks. During the course of the study, enrollment was continued using lower doses of capecitabine (1000 mg/m2 twice daily) and irinotecan (Arm A: 240 mg/m2; Arm B: 120 mg/m2) to improve the safety profile of the combinations. RESULTS Efficacy was evaluable in 134 patients (68 in…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerPhases of clinical researchCOLON CANCERIrinotecanGastroenterologyDeoxycytidineDrug Administration Schedulecolorectal carcinoma first-line treatment irinotecan and capecitabine combination Phase II triallaw.inventionCapecitabineRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisAdverse effectCapecitabineAgedXELIRIbusiness.industryCarcinomaCancerMiddle Agedmedicine.diseaseSurgeryIrinotecanOncologyDrug EvaluationCamptothecinFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drug
researchProduct

Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndrome…

2008

Somatostatin-producing neuroendocrine tumors (SOM-NETs) of the duodenum and pancreas appear to be heterogeneous. To determine their clinicopathological profiles, respective data were analyzed on a series of 82 duodenal and 541 pancreatic NETs. In addition, the clinical records of 821 patients with duodenal or pancreatic NETs were reviewed for evidence of a somatostatinoma syndrome. Predominant or exclusive expression of somatostatin was found in 21 (26%) duodenal and 21 (4%) pancreatic NETs. They were classified as sporadic (n=31) or neurofibromatosis type 1 (NF1)-associated duodenal NETs (n=3), gangliocytic paragangliomas (GCPGs; n=6), or poorly differentiated neuroendocrine carcinomas (pd…

AdultMaleCancer Researchmedicine.medical_specialtyEndocrinology Diabetes and Metabolism610 Medicine & healthNeuroendocrine tumorsGastroenterologyParagangliomaEndocrinologyDuodenal NeoplasmsInternal medicine10049 Institute of Pathology and Molecular PathologySomatostatinomaMultiple Endocrine Neoplasia Type 1MedicineHumansMEN11306 Cancer ResearchGenetic Predisposition to DiseaseNeurofibromatosisMultiple endocrine neoplasia610 Medicine & healthAgedAged 80 and overbusiness.industryIncidenceSyndromeSomatostatinomaMiddle Agedmedicine.diseasePrognosis1310 EndocrinologyPancreatic Neoplasms2712 Endocrinology Diabetes and MetabolismNeuroendocrine Tumorsmedicine.anatomical_structureSomatostatinOncologyDuodenum570 Life sciences; biology2730 OncologyFemalebusinessPancreasSomatostatinFollow-Up Studies
researchProduct

Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Del…

2005

Purpose We performed this phase III study to compare the irinotecan, leucovorin (LV), and fluorouracil (FU) regimen (FOLFIRI) versus the oxaliplatin, LV, and FU regimen (FOLFOX4) in previously untreated patients with advanced colorectal cancer. Patients and Methods A total of 360 chemotherapy-naive patients were randomly assigned to receive, every 2 weeks, either arm A (FOLFIRI: irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2 [LV5FU2]) or arm B (FOLFOX4: oxaliplatin 85 mg/m2 on day 1 with LV5FU2 regi…

AdultMaleCancer Researchmedicine.medical_specialtyRandomizationOrganoplatinum CompoundsColorectal cancerfolinic acidatropineplatinum complexLeucovorinGastroenterologylaw.inventionRandomized controlled trialFolfox protocollawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions Intravenousirinotecanantineoplastic agentAgedbusiness.industryoxaliplatinMiddle Agedmedicine.diseaseSurvival AnalysisOxaliplatinSurgeryIrinotecanRegimenTreatment OutcomeOncologyFluorouracildrug derivativeDisease ProgressionFOLFIRICamptothecinFemaleFluorouracilIFL protocolColorectal Neoplasmsbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Ultrasound-guided fine-needle aspiration cytology in the early detection of melanoma metastases.

2000

BACKGROUND. The early detection and treatment of tumor recurrences in melanoma patients is dependent on reliable, sensitive, and specific techniques to verify suspected tumor metastases. As of now, fine-needle aspiration cytology (FNAC) has yet to establish itself in the routine follow-up of melanoma patients. METHODS. FNAC procedures were performed in melanoma patients with palpable tumors or nonpalpable, ultrasonically suspicious lesions. Cytodiagnostic evaluation of fine-needle samples obtained from suspicious lesions was performed morphologically. Findings were validated either by histopathologic diagnosis or prolonged clinical follow-up. RESULTS. The cytologic examination of 739 FNACs …

AdultMaleCancer Researchmedicine.medical_specialtySkin NeoplasmsAdolescentEarly detectionSensitivity and SpecificityMetastasisFine needle aspiration cytologyCytologyBiopsymedicineHumansSampling (medicine)Neoplasm MetastasisMelanomaUltrasonography InterventionalAgedNeoplasm Stagingmedicine.diagnostic_testbusiness.industryMelanomaUltrasoundBiopsy NeedleReproducibility of ResultsMiddle Agedmedicine.diseasebody regionsOncologyFemaleRadiologybusinessCancer
researchProduct

Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in…

2005

An open-label randomised comparison of efficacy and tolerability of irinotecan plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) (ILF) with etoposide plus 5-FU/LV (ELF) in patients with untreated metastatic or locally advanced gastric cancer. One cycle of ILF comprised six once-weekly infusions of irinotecan 80 mg m(-2), LV 500 mg m(-2), 24-h 5-FU 2000 mg m(-2), and ELF comprised three once-daily doses of etoposide 120 mg m(-2), LV 300 mg m(-2), 5-FU 500 mg m(-2). In all, 56 patients received ILF and 58 ELF. Median age was 62 years, Karnofsky performance 90%, and disease status was comparable for both arms. The objective clinical response rates after 14 weeks treatment (primary end p…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classLeucovorinPhases of clinical researchNeutropeniaAdenocarcinomaIrinotecanAntimetaboliteGastroenterologygastricStomach NeoplasmsInternal medicineClinical StudiesAntineoplastic Combined Chemotherapy ProtocolsMedicineHumans5-fluorouracilStomach cancerEtoposidePeritoneal NeoplasmsAgedEtoposideNeoplasm StagingLevoleucovorinbusiness.industryMiddle Agedmedicine.diseaseSurvival AnalysisSurgerymetastaticIrinotecanELFTreatment OutcomeOncologyTolerabilityFluorouracilCamptothecinFemaleEsophagogastric JunctionFluorouracilbusinessILFmedicine.drugBritish Journal of Cancer
researchProduct

Structure, chromosomal localization, and brain expression of human Cx36 gene

1999

Rat connexin-36 (Cx36) is the first gap junction protein shown to be expressed predominantly in neuronal cells of the mammalian central nervous system. As a prerequisite for studies devoted to the investigation of the possible role of this connexin in human neurological diseases, we report the cloning and sequencing of the human Cx36 gene, its chromosomal localization, and its pattern of expression in the human brain analyzed by radioactive in situ hybridization. The determination of the human gene sequence revealed that the coding sequence of Cx36 is highly conserved (98% identity at the protein level with the mouse and rat Cx36 and 80% with the ortholog perch and skate Cx35), and that the…

AdultMaleCandidate geneAdolescentgenetic structuresMolecular Sequence DataIn situ hybridizationBiologyHippocampal formationPolymerase Chain ReactionConnexinsMiceCellular and Molecular NeurosciencemedicineAnimalsHumansCoding regionAmino Acid SequenceSkates FishCloning MolecularEye ProteinsPeptide Chain Initiation TranslationalGeneIn Situ Hybridization FluorescenceChromosomes Human Pair 15Genomic LibrarySequence Homology Amino Acidmedicine.diagnostic_testBrainChromosome MappingHuman brainMiddle AgedMolecular biologyIntronsRatsmedicine.anatomical_structureSpinal CordOrgan SpecificityPerchesCerebellar cortexFemalesense organsSequence AlignmentFluorescence in situ hybridizationJournal of Neuroscience Research
researchProduct

Re: Antimicrobial Resistance in More Than 100,000 Escherichia coli Isolates According to Culture Site and Patient Age, Gender, and Location

2011

ABSTRACT Escherichia coli and the antimicrobial pressure exerted on this microorganism can be modulated by factors dependent on the host. In this paper, we describe the distribution of antimicrobial resistance to amikacin, tobramycin, ampicillin, amoxicillin clavulanate, cefuroxime, cefoxitin, cefotaxime, imipenem, ciprofloxacin, fosfomycin, nitrofurantoin, and trimetoprim-sulfametoxazole in more than 100,000 E. coli isolates according to culture site and patient age, gender, and location. Bayesian inference was planned in all statistical analysis, and Markov chain Monte Carlo simulation was employed to estimate the model parameters. Our findings show the existence of a marked difference in…

AdultMaleCefotaximeAdolescentmedicine.drug_classUrologyAntibioticsCefotaximeDrug resistanceFosfomycinBiologymedicine.disease_causeEpidemiology and SurveillanceMicrobiologyYoung AdultAntibiotic resistanceFosfomycinCiprofloxacinPatient ageDrug Resistance Multiple BacterialEscherichia coliHumansMedicinePharmacology (medical)ChildAmikacinEscherichia coliEscherichia coli InfectionsAgedRetrospective StudiesAntibacterial agentAged 80 and overPharmacologybusiness.industryInfantMiddle AgedAntimicrobialAnti-Bacterial AgentsImipenemInfectious DiseasesNitrofurantoinAmikacinChild PreschoolTobramycinAmpicillinFemalebusinessmedicine.drugJournal of Urology
researchProduct